Advanced malignant pleural mesothelioma: Experience in 42 patients
Vera Eunice Robles-Pérez 1, Jeannette Liliana Córdova-López 2, Ricardo López-Rodríguez 3, Francisco Javier Meza-Vargas 4, Víctor Hugo Ramos-Cano 5, Eurídice Robles-Pérez 6
1 Cirujano oncólogo, Hospital Regional 1.º de Octubre, ISSSTE, Ciudad de México; 2 Department of Pediatric Cardiology, Hospital Pediátrico de Azcapotzalco, SS CDMX, Mexico City, Mexico; 3 Department of Cardiovascular Anesthesiology, Juarez Hospital in Mexico, SS, Mexico City, Mexico; 4 Department of Neuroanesthesiology, Juarez Hospital in Mexico, SS, Mexico City, Mexico; 5 Department of Cardiovascular Surgery, Hospital Juárez de México, SS, Mexico City, Mexico; 6 Department of Thoracic Surgery, Hospital Juárez de México, SS, Mexico City, Mexico
Vera Eunice Robles-Pérez, Jeannette Liliana Córdova-López, Ricardo López-Rodríguez, Francisco Javier Meza-Vargas, Víctor Hugo Ramos-Cano, Eurídice Robles-Pérez
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondencia: Eurídice Robles-Pérez, Email no disponible
Resumen
Malignant pleural mesothelioma is a rare, difficult to diagnose neoplasm with poor prognosis. To determine the prognostic factors for survival in patients with this disease at advanced stages (Stages III and IV), the medical files of 42 patients with this diagnosis were assessed, and factors known to be prognostic of poor survival were statistically analyzed. Age >60 years and serum albumin levels <3.5 g/dL were highly significant (p < 0.001). The presence of fever, dyspnea, weight loss >10%, and platelets >400,000/µL was highly significant (p < 0.01) and, finally, Eastern Cooperative Oncology Group performance status 3 or 4 and the presence of chest pain and cough were significant (p < 0.05). In contrast with reports in the literature, male gender, known exposure to asbestos, smoking, diabetes, leukocytosis, anemia, lactate dehydrogenase >500 IU/L in pleural fluid, presence of nodular pleural thickening on imaging studies, presence of pleural effusion >60%, mediastinal invasion, site of presentation, biphasic and sarcomatous lineage and forms of treatment showed no significant differences with regard to patient survival in our population. Mean survival was 8.1 months, with values ranging from 30 days to 1 year and 4 months.
